Mode of function of biological anti-TNF agents in the treatment of inflammatory bowel diseases (Q36897403)

16 August 2017

1 reference

title

Mode of function of biological anti-TNF agents in the treatment of inflammatory bowel diseases (English)

1 reference

inflammatory bowel diseases

16 August 2017

main subject

0 references

0 references

Alexander Moschen

2

0 references

Arthur Kaser

series ordinal

3

object named as

Arthur Kaser

1 reference

16 August 2017

Herbert Tilg

1

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 July 2007

1 reference

Expert Opinion on Biological Therapy

16 August 2017

published in

1 reference

16 August 2017

volume

7

1 reference

16 August 2017

issue

7

1 reference

16 August 2017

page(s)

1051-1059

1 reference

Inflammatory Bowel Disease

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

Medical therapy for ulcerative colitis 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

Network communications: lymphotoxins, LIGHT, and TNF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

Tumor necrosis factor: biology and therapeutic inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

New concepts in the pathophysiology of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

The immunological and genetic basis of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

Reciprocal IFN-gamma and TGF-beta responses regulate the occurrence of mucosal inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

The role of the tumor necrosis factor receptor in 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

Infliximab induces apoptosis of monocytes and T lymphocytes in a human-mouse chimeric model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

How T lymphocytes switch between life and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

Cloning of TRAP, a ligand for CD40 on human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

Laboratory markers in IBD: useful, magic, or unnecessary toys?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

Infliximab treatment reduces complement activation in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

Predictors of response to infliximab in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

Genetic testing in Crohn disease: utility in individualizing patient management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

Differential p38 mitogen-activated protein kinase target phosphorylation in responders and nonresponders to infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1051

10.1517/14712598.7.7.1051

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference